These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 25636086)
41. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759 [TBL] [Abstract][Full Text] [Related]
42. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. Shi JY; Xing Q; Duan M; Wang ZC; Yang LX; Zhao YJ; Wang XY; Liu Y; Deng M; Ding ZB; Ke AW; Zhou J; Fan J; Cao Y; Wang J; Xi R; Gao Q Oncotarget; 2016 Jan; 7(3):2867-77. PubMed ID: 26672766 [TBL] [Abstract][Full Text] [Related]
43. PBRM1 loss is a late event during the development of cholangiocarcinoma. Luchini C; Robertson SA; Hong SM; Felsenstein M; Anders RA; Pea A; Nottegar A; Veronese N; He J; Weiss MJ; Capelli P; Scarpa A; Argani P; Kapur P; Wood LD Histopathology; 2017 Sep; 71(3):375-382. PubMed ID: 28394406 [TBL] [Abstract][Full Text] [Related]
44. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma]. Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828 [TBL] [Abstract][Full Text] [Related]
45. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Chong DQ; Zhu AX Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149 [TBL] [Abstract][Full Text] [Related]
47. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3. Boorjian S Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671 [TBL] [Abstract][Full Text] [Related]
51. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum. Morcos M; Dubois S; Bralet MP; Belghiti J; Degott C; Terris B Am J Clin Pathol; 2001 Nov; 116(5):738-43. PubMed ID: 11710692 [TBL] [Abstract][Full Text] [Related]
52. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Seok JY; Na DC; Woo HG; Roncalli M; Kwon SM; Yoo JE; Ahn EY; Kim GI; Choi JS; Kim YB; Park YN Hepatology; 2012 Jun; 55(6):1776-86. PubMed ID: 22234953 [TBL] [Abstract][Full Text] [Related]
53. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428 [TBL] [Abstract][Full Text] [Related]
55. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683 [TBL] [Abstract][Full Text] [Related]
56. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301 [TBL] [Abstract][Full Text] [Related]
57. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104 [TBL] [Abstract][Full Text] [Related]
58. Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation. Chuensumran U; Saelee P; Punyarit P; Wongkham S; Pairojkul C; Chauin S; Petmitr S Asian Pac J Cancer Prev; 2011; 12(3):775-9. PubMed ID: 21627382 [TBL] [Abstract][Full Text] [Related]
59. Molecular features of primary hepatic undifferentiated carcinoma. Tsai JH; Jeng YM; Lee CH; Liau JY Mod Pathol; 2022 May; 35(5):680-687. PubMed ID: 34949765 [TBL] [Abstract][Full Text] [Related]
60. Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids. Artegiani B; van Voorthuijsen L; Lindeboom RGH; Seinstra D; Heo I; Tapia P; López-Iglesias C; Postrach D; Dayton T; Oka R; Hu H; van Boxtel R; van Es JH; Offerhaus J; Peters PJ; van Rheenen J; Vermeulen M; Clevers H Cell Stem Cell; 2019 Jun; 24(6):927-943.e6. PubMed ID: 31130514 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]